Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 11, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 370,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,495.5 pence per share; lowest price paid was 1,483.5 pence per share.
- Treasury Holdings (Settled): 494,951,327 shares (9.16% of total issued share capital).
- Treasury Holdings (Including Unsettled): 496,061,327 shares (10.11% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,700,629 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 370,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual reports to confirm the 9.16% ownership stake.
- Confirm the settlement status of the 1,110,000 shares included in the "unsettled" treasury count to determine the exact voting rights denominator.
- Review the remaining authorization for share repurchases under the mandate granted on May 3, 2012.